Edward Ludwig Purchases 3,580 Shares of Boston Scientific (NYSE:BSX) Stock

Boston Scientific Corporation (NYSE:BSX) Director Edward Ludwig purchased 3,580 shares of the company’s stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the transaction, the director directly owned 25,359 shares in the company, valued at approximately $1,437,348.12. The trade was a 16.44% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website.

Boston Scientific Stock Up 1.0%

Shares of NYSE BSX opened at $57.71 on Friday. Boston Scientific Corporation has a one year low of $52.52 and a one year high of $109.50. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The business’s fifty day moving average price is $61.97 and its 200-day moving average price is $80.25. The stock has a market capitalization of $85.77 billion, a PE ratio of 24.15, a P/E/G ratio of 1.05 and a beta of 0.62.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. During the same quarter in the prior year, the firm earned $0.75 EPS. The business’s revenue for the quarter was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, equities research analysts anticipate that Boston Scientific Corporation will post 3.38 EPS for the current year.

Boston Scientific announced that its Board of Directors has initiated a share repurchase program on Monday, May 18th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board believes its stock is undervalued.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Several Boston Scientific directors bought shares this week, including Cheryl Pegus, David C. Habiger, and Edward J. Ludwig. Heavy insider buying often signals management confidence and can help support sentiment around BSX. Article Title
• Positive Sentiment: Boston Scientific’s board authorized a $5 billion share repurchase program, which can be viewed as a sign that management believes the stock may be undervalued and could provide downside support. Article Title
• Positive Sentiment: Boston Scientific recently reported earnings and revenue that slightly beat expectations and raised guidance for 2026, reinforcing the company’s longer-term growth story even though the stock has remained weak.
• Neutral Sentiment: Recent analyst commentary has been mixed: firms like Baird and Stifel still have positive ratings, but several price targets were trimmed, suggesting Wall Street remains constructive while tempering expectations. Article Title
• Negative Sentiment: Coverage asking why BSX is down 13% since its last earnings report highlights lingering investor concern that the stock has not kept pace with its fundamentals, likely weighing on near-term trading. Article Title

Hedge Funds Weigh In On Boston Scientific

Several institutional investors have recently modified their holdings of the company. Vanguard Group Inc. grew its position in Boston Scientific by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock worth $13,319,060,000 after acquiring an additional 1,436,550 shares during the last quarter. State Street Corp grew its position in Boston Scientific by 1.4% during the 4th quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock worth $6,278,422,000 after acquiring an additional 920,495 shares during the last quarter. Capital World Investors grew its position in Boston Scientific by 1.9% during the 4th quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock worth $2,588,953,000 after acquiring an additional 502,627 shares during the last quarter. Norges Bank bought a new position in Boston Scientific during the 4th quarter worth approximately $2,199,395,000. Finally, Morgan Stanley grew its position in Boston Scientific by 10.8% during the 4th quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock worth $2,189,289,000 after acquiring an additional 2,246,308 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Robert W. Baird dropped their price objective on Boston Scientific from $78.00 to $75.00 and set an “outperform” rating on the stock in a report on Tuesday. Wall Street Zen cut Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Barclays decreased their target price on Boston Scientific from $124.00 to $96.00 and set an “overweight” rating on the stock in a research note on Thursday, April 23rd. Citigroup decreased their target price on Boston Scientific from $94.00 to $87.00 and set a “buy” rating on the stock in a research note on Tuesday, April 7th. Finally, Oppenheimer set a $90.00 target price on Boston Scientific in a research note on Thursday, April 23rd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $92.71.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.